Quantcast

Latest ramipril Stories

2011-04-29 13:37:39

The angiotensin-converting enzyme (ACE) inhibitor drug, ramipril, is particularly effective in lowering the risk of end-stage renal disease (ESRD) in obese patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). "Obese patients with kidney disease progress more quickly towards renal failure compared to non-obese patients, and ramipril virtually abolishes this excess risk," comments Carmine Zoccali, MD (CNR-IBIM and Ospedali...

2011-04-29 06:11:07

(Ivanhoe Newswire) --A drug used to treat high blood pressure may reduce the risk of kidney failure in obese patients. Research studies have found that an obese person is nearly seven-times more likely to develop kidney failure than a normal-weight person. An angiotensin-converting enzyme (ACE) inhibitor drug, known as ramipril, has proven to be effective in lowering the risk of end-stage renal disease (ESRD) in these patients. For the study, researchers analyzed data from another trial that...

2011-03-02 00:01:00

HOBOKEN, N.J., March 2, 2011 /PRNewswire/ -- The American Heart Association estimates 35 percent of adults in the U.S. suffer from metabolic syndrome, a group of risk factors characterized by obesity and the simultaneous presence of heart disease risk factors with high blood pressure, blood sugar and lipids. In patients with metabolic syndrome, high blood pressure and blood glucose gradually impair kidney function, which in turn affects the organ's ability to filter waste from the body....

2010-06-13 14:59:00

RIDGEFIELD, Conn., June 13 /PRNewswire/ -- Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the...

2010-04-27 18:00:00

DEERFIELD, Ill. and OSAKA, Japan, April 27 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to...

2010-03-03 13:20:23

Research reveals Pycnogenol lowers elevated urinary protein levels and improves blood flow to the kidneys An estimated one in ten adults suffers from kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases. A leading cause of kidney disease is hypertension, which effects one out of every four U.S. adults. Chronically high blood pressure damages capillaries of the kidneys which in turn affects the organ's ability to filter waste and remove excess...

2010-03-02 23:01:00

HOBOKEN, N.J., March 3 /PRNewswire/ -- An estimated one in ten adults suffers from kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases. A leading cause of kidney disease is hypertension, which effects one out of every four U.S. adults. Chronically high blood pressure damages capillaries of the kidneys which in turn affects the organ's ability to filter waste and remove excess fluids from the body. A study published in the March 2010 issue of...

2009-10-19 07:30:00

RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular...

2009-07-23 13:05:17

A class of medication used to treat high blood pressure may protect older adults against memory decline, U.S. researchers said. High blood pressure is an important risk factor for Alzheimer's disease and vascular dementia, lead author Dr. Kaycee Sink of Wake Forest University School of Medicine says in a statement. Our study found that all blood pressure medications may not be equal when it comes to reducing the risk of dementia in patients with hypertension. The researchers analyzed data...

2009-07-23 08:39:21

A particular class of medication used to treat high blood pressure could protect older adults against memory decline and other impairments in cognitive function, according to a newly published study from Wake Forest University School of Medicine.Research suggests that some of the drugs classified as angiotensin-converting enzyme (ACE) inhibitors, specifically those types of ACE inhibitors that affect the brain by crossing the blood-brain barrier, may reduce inflammation that could contribute...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related